ES2490610T3 - Materiales y métodos para la administración mínimamente invasiva de una composición fluida que contiene células - Google Patents

Materiales y métodos para la administración mínimamente invasiva de una composición fluida que contiene células Download PDF

Info

Publication number
ES2490610T3
ES2490610T3 ES09013159.0T ES09013159T ES2490610T3 ES 2490610 T3 ES2490610 T3 ES 2490610T3 ES 09013159 T ES09013159 T ES 09013159T ES 2490610 T3 ES2490610 T3 ES 2490610T3
Authority
ES
Spain
Prior art keywords
fluid composition
materials
methods
composition containing
minimally invasive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09013159.0T
Other languages
English (en)
Inventor
Helen Marie Nugent
Elazer Edelman
Steve Bollinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Regenerative Medicine LLC
Original Assignee
Shire Regenerative Medicine LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Regenerative Medicine LLC filed Critical Shire Regenerative Medicine LLC
Application granted granted Critical
Publication of ES2490610T3 publication Critical patent/ES2490610T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Una composición fluida que comprende una matriz biocompatible y células endoteliales o células que tienen un fenotipo de tipo endotelial, para utilización en el tratamiento de un tejido isquémico, en donde dicha composición fluida se administra por inyección percutánea a un sitio extraluminal en, o adyacente a, o en la proximidad del tejido isquémico en una cantidad eficaz para tratar el tejido isquémico.
ES09013159.0T 2004-12-08 2005-12-06 Materiales y métodos para la administración mínimamente invasiva de una composición fluida que contiene células Expired - Lifetime ES2490610T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63415504P 2004-12-08 2004-12-08
US634155P 2004-12-08
US66385905P 2005-03-21 2005-03-21
US663859P 2005-03-21
US68205405P 2005-05-18 2005-05-18
US682054P 2005-05-18

Publications (1)

Publication Number Publication Date
ES2490610T3 true ES2490610T3 (es) 2014-09-04

Family

ID=36578486

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09013159.0T Expired - Lifetime ES2490610T3 (es) 2004-12-08 2005-12-06 Materiales y métodos para la administración mínimamente invasiva de una composición fluida que contiene células
ES05848586T Expired - Lifetime ES2339798T3 (es) 2004-12-08 2005-12-06 Materiales y metodos para la administracion minimamente invasiva de una composicion fluida que contiene celulas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05848586T Expired - Lifetime ES2339798T3 (es) 2004-12-08 2005-12-06 Materiales y metodos para la administracion minimamente invasiva de una composicion fluida que contiene celulas.

Country Status (11)

Country Link
US (8) US20080119946A1 (es)
EP (5) EP2184077B1 (es)
JP (8) JP2008522738A (es)
CN (4) CN101912637A (es)
AT (2) ATE474608T1 (es)
AU (4) AU2005314263B2 (es)
CA (4) CA2589588C (es)
DE (2) DE602005018103D1 (es)
ES (2) ES2490610T3 (es)
IL (5) IL183786A (es)
WO (1) WO2006062962A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
DE602006014814D1 (de) 2005-04-21 2010-07-22 Massachusetts Inst Technology Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene, einschliesslich genidentischer und nicht-genidentischer zellen, gewebe oder organe
EP1901680B1 (en) * 2005-06-21 2015-04-15 Shire Regenerative Medicine, Inc. Crypreservation of biocompatible material
ATE502575T1 (de) 2006-06-02 2011-04-15 St Michaels Hospital Ultraschalluntersuchung von venösen strukturen
WO2008057590A2 (en) * 2006-11-07 2008-05-15 Pervasis Therapeutics, Inc. Methods and compositions for modulating tissue modeling
WO2008057580A2 (en) * 2006-11-07 2008-05-15 Pervasis Therapeutics, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
US20100239671A1 (en) 2007-11-06 2010-09-23 Edelman Elazer R Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair
US8409228B2 (en) 2008-06-06 2013-04-02 Duane D. Blatter Tissue management methods, apparatus, and systems
US11197952B2 (en) 2009-01-29 2021-12-14 Advent Access Pte. Ltd. Vascular access ports and related methods
US8337464B2 (en) 2009-01-29 2012-12-25 Vital Access Corporation Vascular access ports and related methods
US9179901B2 (en) 2009-01-29 2015-11-10 Vital Access Corporation Vascular access ports and related methods
EP3878403A1 (en) * 2010-01-27 2021-09-15 Vascular Therapies, Inc. Device for preventing stenosis at an anastomosis site
US8551130B2 (en) 2010-02-18 2013-10-08 Cardiovascular Systems, Inc. Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit
US9050414B2 (en) 2010-02-19 2015-06-09 Cardiovascular Systems, Inc. Systems and methods for mixing therapeutic agents before and/or during administration
US20110277778A1 (en) * 2010-05-14 2011-11-17 Tyco Healthcare Group Lp System and Method for Diverticulitis Treatment
CA2800731A1 (en) * 2010-05-28 2011-12-01 Garnet Biotherapeutics, Inc. Compositions and methods of using living and non-living bioactive devices with components derived from self-renewing colony forming cells cultured and expanded in vitro
JP6356065B2 (ja) * 2011-08-01 2018-07-11 ラミネート・メディカル・テクノロジーズ・リミテッド 外部血管支持体
US9433722B2 (en) * 2011-08-09 2016-09-06 Abbott Cardiovascular Systems Inc. Vascular shield and delivery system
KR102260851B1 (ko) * 2011-08-17 2021-06-08 아르티오 메디컬 인크. 환자의 말초 정맥의 전체 직경 및 루멘 직경을 증가시키기 위한 시스템
US9937296B2 (en) * 2012-07-26 2018-04-10 Agency For Science, Technology And Research Vascular access device and guiding portion
AU2013298145B2 (en) 2012-08-01 2017-11-23 Laminate Medical Technologies Ltd. Apparatus for configuring an arteriovenous fistula
US20150370707A1 (en) * 2014-06-24 2015-12-24 Qualcomm Incorporated Disunited shared-information and private-information caches
US20160029996A1 (en) * 2014-08-01 2016-02-04 Eric Johnson Device and method for using ivus data to characterize and evaluate a vascular graft condition
CN108271770B (zh) * 2017-01-06 2021-06-22 中国科学院化学研究所 微米颗粒在低温冻存中的应用
US11147582B2 (en) 2018-06-14 2021-10-19 Cardio Flow, Inc. Atherectomy devices and methods
EP3809983B1 (en) * 2018-06-22 2025-08-27 Mayo Foundation for Medical Education and Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
KR20210134323A (ko) * 2019-01-31 2021-11-09 베이징 사이토니체 바이오테크놀로지 씨오., 엘티디. 줄기 세포의 대규모 제조를 위한 3차원 배양 방법
IT201900009318A1 (it) * 2019-06-18 2020-12-18 Gianni Pecorari Dispositivo di accesso vascolare per emodialisi permanentemente impiantabile in un paziente avente una fistola arterovenosa ed una confezione sterile contenente un dispositivo monouso di prelievo e/o d’immissione di sangue detta fistola arterovenosa
EP3986502B1 (en) * 2019-06-18 2024-10-16 Emodial S.r.l. Implantable vascular access device
IT202000013321A1 (it) 2020-06-05 2021-12-05 Gianni Pecorari Dispositivo di accesso vascolare per emodialisi permanentemente impiantabile in un paziente, dispositivo di cicatrizzazione di accesso vascolare e confezione sterile contenente un dispositivo monouso di prelievo e/o di immissione di sangue utilizzabile in emodialisi
JPWO2021161884A1 (es) * 2020-02-14 2021-08-19
US12310836B2 (en) 2020-03-03 2025-05-27 Akeo Hagiwara Vein cover
EP4115915A4 (en) * 2020-03-03 2024-04-03 Akeo Hagiwara Vein cover
WO2023037859A1 (ja) * 2021-09-08 2023-03-16 明郎 萩原 血管カバー
JPWO2023037861A1 (es) * 2021-09-08 2023-03-16
US11931501B2 (en) 2022-07-07 2024-03-19 Evan T. Neville Dialysis sheath for use in accessing a dialysis arteriovenous graft or fistula and methods of use
US12004771B1 (en) 2023-06-27 2024-06-11 Cardio Flow, Inc. Rotational atherectomy devices and methods

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418691A (en) * 1981-10-26 1983-12-06 Massachusetts Institute Of Technology Method of promoting the regeneration of tissue at a wound
US4787900A (en) * 1982-04-19 1988-11-29 Massachusetts Institute Of Technology Process for forming multilayer bioreplaceable blood vessel prosthesis
US4820626A (en) * 1985-06-06 1989-04-11 Thomas Jefferson University Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself
IL78950A (en) * 1985-06-06 1991-12-15 Univ Jefferson Coating for prosthetic devices
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US4675002A (en) * 1985-12-02 1987-06-23 Viles Joseph M Liver assist device employing transformed cell lines
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
CA1340581C (en) * 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5567612A (en) * 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
US5736372A (en) * 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US6309635B1 (en) * 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
CH676195A5 (es) * 1988-10-07 1990-12-28 Sulzer Ag
WO1991007154A1 (en) * 1989-11-13 1991-05-30 President And Fellows Of Harvard College EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5540928A (en) * 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5246451A (en) * 1991-04-30 1993-09-21 Medtronic, Inc. Vascular prosthesis and method
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
US5399665A (en) * 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) * 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5575686A (en) * 1993-04-14 1996-11-19 Burndy Corporation Stacked printed circuit boards connected in series
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US6176874B1 (en) * 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
JPH10509696A (ja) * 1994-10-12 1998-09-22 フォーカル， インコーポレイテッド 生分解性ポリマーを介する標的化送達
US6911216B1 (en) * 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US5914268A (en) * 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US5591226A (en) * 1995-01-23 1997-01-07 Schneider (Usa) Inc. Percutaneous stent-graft and method for delivery thereof
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5766584A (en) * 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
US6615071B1 (en) * 1995-09-20 2003-09-02 Board Of Regents, The University Of Texas System Method and apparatus for detecting vulnerable atherosclerotic plaque
US6480743B1 (en) * 2000-04-05 2002-11-12 Neuropace, Inc. System and method for adaptive brain stimulation
US6102884A (en) * 1997-02-07 2000-08-15 Squitieri; Rafael Squitieri hemodialysis and vascular access systems
US6886568B2 (en) * 1998-04-08 2005-05-03 The Johns Hopkins University Method for fabricating cell-containing implants
CA2351671A1 (en) * 1998-11-24 2000-06-08 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6387116B1 (en) * 1999-06-30 2002-05-14 Pharmasonics, Inc. Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts
US6584590B1 (en) * 1999-08-13 2003-06-24 Lucent Technologies Inc. JTAG port-sharing device
US6555374B1 (en) * 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
NZ518759A (en) * 1999-10-05 2004-10-29 Transkaryotic Therapies Inc Hybrid matrices and hybrid matrix mixtures
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US20010047843A1 (en) * 1999-12-22 2001-12-06 Reinig Maureen Louise Handicraft process for creating cards
WO2001062241A1 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
AU4566001A (en) * 2000-03-13 2001-09-24 Biocure Inc Embolic compositions
ATE362382T1 (de) * 2000-03-15 2007-06-15 Orbusneich Medical Inc Beschichtung welche ein anhaften von endothelzellen stimuliert
US6506398B1 (en) * 2000-04-28 2003-01-14 Hosheng Tu Device for treating diabetes and methods thereof
EP1301197A2 (en) * 2000-07-21 2003-04-16 The Board Of Regents, The University Of Texas System Device providing regulated growth factor delivery for the regeneration of peripheral nerves
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6622031B1 (en) * 2000-10-04 2003-09-16 3Com Corporation Antenna flip-up on removal of stylus for handheld device
JP3580239B2 (ja) * 2000-10-19 2004-10-20 日本電気株式会社 言語選択同報システム及び言語選択同報方法
US6565601B2 (en) * 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
EP1356071B1 (en) * 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
ATE481097T1 (de) * 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit
US6969373B2 (en) * 2001-04-13 2005-11-29 Tricardia, Llc Syringe system
US20030036720A1 (en) * 2001-08-17 2003-02-20 Spencer Dudley W.C. Hemodialysis assembly and method
US6808518B2 (en) * 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US20040047843A1 (en) * 2002-02-12 2004-03-11 Uab Research Foundation Method for spinal cord reconnection
US20050008629A1 (en) * 2002-05-08 2005-01-13 Interpore Orthopaedics, A Delaware Corporation Encapsulated AGF cells
CA2490811A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
US20040156878A1 (en) * 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
US20040215220A1 (en) * 2003-04-24 2004-10-28 Dolan Mark J. Anastomotic stent, apparatus and methods of use thereof
WO2005049105A2 (en) * 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
US20050106554A1 (en) * 2003-11-19 2005-05-19 Palecek Sean P. Cryopreservation of pluripotent stem cells
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US20060004316A1 (en) * 2004-07-02 2006-01-05 Difiore Attilio E Reduction of recirculation in catheters
US7976517B2 (en) * 2004-09-30 2011-07-12 Codman & Shurtleff, Inc. Fluid management flow implants of improved occlusion resistance
US7882863B2 (en) * 2005-10-19 2011-02-08 Cd Solutions, Llc Apparatus and method for mixing and transferring medications
EP1951344B1 (en) * 2005-11-07 2014-05-28 Industrie Borla SpA Vented safe handling vial adapter

Also Published As

Publication number Publication date
IL183785A (en) 2013-03-24
JP2015042682A (ja) 2015-03-05
CN103055350B (zh) 2014-12-10
IL183784A0 (en) 2008-04-13
AU2010249280B2 (en) 2012-10-18
AU2005314263A1 (en) 2006-06-15
WO2006062962A3 (en) 2006-10-12
HK1112428A1 (en) 2008-09-05
US20110229549A1 (en) 2011-09-22
JP2013039431A (ja) 2013-02-28
JP2012148164A (ja) 2012-08-09
ATE450276T1 (de) 2009-12-15
CN101940801B (zh) 2014-04-16
JP2008522738A (ja) 2008-07-03
US20100318016A1 (en) 2010-12-16
CA2589588A1 (en) 2006-06-15
IL183786A0 (en) 2007-09-20
ATE474608T1 (de) 2010-08-15
IL183785A0 (en) 2007-09-20
ES2339798T3 (es) 2010-05-25
AU2005314312A1 (en) 2006-06-15
CA2881343A1 (en) 2006-06-15
EP2226036A1 (en) 2010-09-08
DE602005018103D1 (de) 2010-01-14
EP1824417A2 (en) 2007-08-29
CA2589597A1 (en) 2006-06-15
JP2008522735A (ja) 2008-07-03
EP1824526B1 (en) 2009-12-02
CN101912637A (zh) 2010-12-15
HK1112429A1 (en) 2008-09-05
JP2008532565A (ja) 2008-08-21
IL183786A (en) 2011-06-30
CA2589871A1 (en) 2006-06-15
DE602005022481D1 (de) 2010-09-02
EP1824526A2 (en) 2007-08-29
AU2005314263B2 (en) 2011-05-19
IL212764A0 (en) 2011-07-31
US20080125858A1 (en) 2008-05-29
CN102772824A (zh) 2012-11-14
WO2006062962A2 (en) 2006-06-15
US20130052166A1 (en) 2013-02-28
JP5674256B2 (ja) 2015-02-25
CA2589588C (en) 2013-10-15
JP2013056202A (ja) 2013-03-28
IL183784A (en) 2011-03-31
US20080119946A1 (en) 2008-05-22
CN101940801A (zh) 2011-01-12
IL209574A (en) 2013-08-29
CN103055350A (zh) 2013-04-24
IL209574A0 (en) 2011-01-31
AU2005314226A1 (en) 2006-06-15
JP2012176260A (ja) 2012-09-13
CA2589597C (en) 2015-04-21
US20110045054A1 (en) 2011-02-24
AU2005314226B2 (en) 2011-05-19
EP1824529A2 (en) 2007-08-29
EP2184077A1 (en) 2010-05-12
AU2010249280A1 (en) 2011-01-06
US20080118561A1 (en) 2008-05-22
US20110002973A1 (en) 2011-01-06
AU2005314312B2 (en) 2010-10-07
EP1824529B1 (en) 2010-07-21
EP2184077B1 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
ES2490610T3 (es) Materiales y métodos para la administración mínimamente invasiva de una composición fluida que contiene células
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
AR062522A1 (es) Tratamiento de desordenes en cartilagos
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ATE545441T1 (de) Verfahren und vorrichtungen zur minimal invasiven abgabe von zellhaltigen fliessfähigen zusammensetzungen
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
BRPI0904961A2 (pt) Dispositivo médico implantável, depósito de fármaco e método de administrar um agente biologicamente ativo e clonidina ou um derivado da mesma a um tecido e de produzir um depósito de fármaco
BRPI0820800A2 (pt) Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente
ECSP099427A (es) Barra de Tierra Segunda Generación 16 conexiones
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
ECSP10010589A (es) Farmaco contra el cancer de higado
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
RU2013132566A (ru) Терапевтическое средство от грыжи межпозвоночного диска
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
MD3905G2 (ro) Remediu medicamentos cu acţiune prelungită sub formă de gel pentru tratamentul afecţiunilor parodonţiului (variante)
DK1974721T3 (da) Injiceringsdygtig steril farmaceutisk sammensætning med natriumpiperacillin og natriumtazobactam som aktive stoffer
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона